CN106581263A - Pharmaceutical composition for treating lumbar disc herniation and preparation method thereof - Google Patents

Pharmaceutical composition for treating lumbar disc herniation and preparation method thereof Download PDF

Info

Publication number
CN106581263A
CN106581263A CN201611132987.8A CN201611132987A CN106581263A CN 106581263 A CN106581263 A CN 106581263A CN 201611132987 A CN201611132987 A CN 201611132987A CN 106581263 A CN106581263 A CN 106581263A
Authority
CN
China
Prior art keywords
pharmaceutical composition
weight portion
weight
ethanol
intervertebral disc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201611132987.8A
Other languages
Chinese (zh)
Inventor
不公告发明人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jinan Haoyu Qingtian Medicine Technology Co ltd
Original Assignee
Jinan Haoyu Qingtian Medicine Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jinan Haoyu Qingtian Medicine Technology Co ltd filed Critical Jinan Haoyu Qingtian Medicine Technology Co ltd
Priority to CN201611132987.8A priority Critical patent/CN106581263A/en
Publication of CN106581263A publication Critical patent/CN106581263A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/55—Liquid-liquid separation; Phase separation

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a pharmaceutical composition for treating lumbar disc herniation and a preparation method thereof. The pharmaceutical composition is prepared from Herba Sopubiae Trifidae, root of denseflower Euonymus, hydroxyevodiamine, root or stem of hairyleaf chonemorpha, and asiatic acid, may be made into various forms of drug according to conventional preparation processes, and has significant effect for treating lumbar disc herniation.

Description

Pharmaceutical composition for the treatment of prolapse of lumbar intervertebral disc and preparation method thereof
Technical field
The invention belongs to technical field of Chinese medicines, more particularly to a kind of pharmaceutical composition and its system for treating prolapse of lumbar intervertebral disc Preparation Method.
Background technology
Clinically, prolapse of lumbar intervertebral disc is a kind of common and multiple orthopaedic disease, while also causing patient to occur Lumbago and skelalgia.Caused by present major part lumbago companion sciatica is because of prolapse of lumbar intervertebral disc.In addition, prolapse of lumbar intervertebral disc is suffered from Person is also in larger pain, and Damage of cauda nerve person also has fecal and urinary functionses obstacle, so as to make to patient's daily life quality Into severity effect.Prolapse of lumbar intervertebral disc（Lumbar disc herniation, LDH, hereinafter referred to as waist dash forward disease）It is a kind of Common clinical, frequently-occurring disease, are one of modal causes of disease of lumbago and skelalgia.The treatment of prolapse of lumbar intervertebral disc at present substantially can be divided into Non-operative treatment and operative therapy.Therapeutic selection depends on age, the course of disease, pathologic stage and clinical manifestation of patient etc.. Most patients all can Jing non-operative treatment be eased or improve, have the late result of two kinds of therapies of more research prompting Similar, its curative effect indicator difference is simultaneously not statistically signigicant.In Chinese medicine, prolapse of lumbar intervertebral disc category " lumbago ", " numbness The categories such as card ", this disease is mainly relevant with patients blood, visceral dysfunction etc., while it is tight also presence to occur with lumbago Contact.Waist for kidney internal organs, therefore the presence of the disease and human kidney is closely connected.《Medicine Comprehended》：" lumbago contracture draws lower limb Foot ".《Plain Questions. numbness opinion》Point out that " gas of wind, cold, wet three is miscellaneous extremely, combined into numbness."《Danxi's experiential therapy. lumbago》Then think lumbago diseases because " The understanding such as main damp and hot, kidney deficiency, blood stasis, sprain and contusion, accumulation of phlegm ".
Radix seu caulis chonemorphae valvatae：For Apocynaceae Chonemorpha eriostylis platymiscium hair leaf Radix seu caulis chonemorphae valvatae：Root, the stem of Chonemorpha valvata Chatt And peel of stem.Whole year can adopt, and clean, and dry.【Nature and flavor】It is sweet；Slight bitter；Slightly warm in nature；Mild toxicity.【Indication】Dispelling, collateral-activating；Only Blood.Main rheumatic arthritis；Fracture；Traumatic hemorrhage.【Former phytomorph】Sturdy woody climber.Sprout is by yellow pubescence, Quan Lin Has abundant milk.Leaf opposite, width egg shape or subcircular, long 15-30cm, wide 10-20cm, tip is suddenly sharp or perfectly round, base portion circle Shape, blade back is by pubescence；Vein is obvious.Basidixed cyme, flower pale red；Calyx 5 is split to base portion, and splinter forceps closes shape arrangement, Inner face base portion has dentation body of gland；The nearly high foot disk like of corolla, tube inner face is covered to the right by close pubescence, sliver；Stamen is born in Tube middle part, flower pesticide arrow shaped, filigree is by micro- pubescence；Floral disc ring-type, tip is shallow to be split；Constituted from raw carpel by 2 pieces in room, flower Post is thread, and tip is by microtriche.Follicle radish is twin parallel.Seed is flat, and tip has long thin,tough silk matter kind hair.Spring at florescence, summer, the fruiting period autumn, Winter.Record in dictionary of medicinal plant.
Herba sopubiae Trifidae：This product is complete for the short hat grass Sopubia trfida Buch.-Ham.'s of Scrophulariaceae Sopubia plant Grass.Summer, autumn harvesting, dry.【Nature and flavor】Bitter in the mouth；It is puckery；It is warm in nature.【Indication】Expelling wind and removing dampness；Wet inner pain relieving.Main wind and cold is wet Numbness；Stomachache with cool feeling；Lumbago due to renal deficiency.【Former phytomorph】Short hat grass annual herb, high 40-90cm.Root is carefully cylindrical.Stem list One or more numbers, uprightly, top multi-branched, branch has corner angle and striped, by pubescence.Leaf opposite or alternate；The full shape synthesis circle of blade Taper；Luxuriant leave shape；Bennet is about 1cm, there is a pair of brill shape squamellas at nearly top；Calyx taper；Bract is lobate；Bennet is about 1cm, There are a pair of brill shape squamellas at nearly top；Calyx bracelet shape, pipe portion 10, rib of tool, calyx tooth 5 is wider than in length, triangle, internal and edge without There is MIAOMAO；Corolla yellow or purple, are about 1cm, manage extremely short, sliver 5, carry out, obovate greatly, and circle is blunt, near equal；Stamen 4, The last two, filigree is born in the top of tube, and the Room of flower pesticide 1 is degenerated and narrow；Style is single, harbors.Capsule is spherical, and tip is flat And be recessed, it is shorter or isometric than calyx.Shape of the seed is uneven, the reticulate pattern for having elongated hole.The month at florescence 6-7, fruiting period September.Record big in Chinese medicine Dictionary.
Radix Euonymi myrianthi：For root, the stem of Celastraceae burning buss Radix Euonymi myrianthi Euonymus myrianthus Hemsl.. Root, harvests after autumn, cleans, and section is dried；Stem, summer, autumn harvesting, cutting is dried.【Nature and flavor】It is sweet；Slight bitter；It is flat.【Return through】 Liver；Spleen；Kidney channel.【Indication】Kidney tonifying strengthens waist；Blood stasis dispelling dampness removing.Main lumbago due to renal deficiency；Frequent fetal movement；Chronic nephritiss；Lochia Not to the utmost；Injury and bone fracture；Rheumatic arthralgia；Leukorrhagia.【Former phytomorph】Big fruit lance defends shrub, up to 6m.Leaf opposite；The long 5- of petiole 8mm；Keratin, ovum shape lanceolar is to oblong, and long 5-13cm, wide 3-4.5cm, tip is tapering, edge pure circle serration.Flower The nearly basidixed of sequence, many times branch shape spends more thyrse；Flower yellow, diameter 7-10mm, 4 numbers, stamen has extremely short filigree.Capsule Golden yellow, obovate or the cone of falling ovate, are about 1.5cm, diameter about 1cm.Seed has orange-yellow aril.Record in Chinese medicine Voluminous dictionary.
Hydroxyevodiamine（Hydroxyevodiamine）：CAS 1238-43-3, molecular formula C19H17N3O2, molecular weight 319.36.【Ingredient origin】Fructus Evodiae Evodia rutaecarpa..
Asiatic acid（Asiatic acid）：CAS 464-92-6, molecular formula C30H48O5, molecular weight 488.70.【It is biological Activity】Help to create new connective tissue;Promote wound healing (external)；Promote epidermal cornified;Granulation is stimulated to occur. 【Ingredient origin】Borneolum Syntheticum Dryobalanops aromatics, Herba Centellae Centella asiatica.
The structure of 2 crude drug：
Asiatic acid（Asiatic acid）Hydroxyevodiamine（Hydroxyevodiamine）.
The content of the invention
The purpose of the present invention is to overcome the shortcomings of background technology, there is provided a kind of medicine group of effectively treatment prolapse of lumbar intervertebral disc Compound and preparation method thereof.
The present invention adopts the following technical scheme that realization：
The composition and weight portion for making the crude drug of the pharmaceutical composition of the treatment prolapse of lumbar intervertebral disc be：
Herba sopubiae Trifidae 562-568 weight portion Radix Euonymi myrianthi 500-506 weight portion Hydroxyevodiamine 204-208 weight portion rattans Secondary 50-60 weight portions asiatic acid 12-14 weight portions.
The pharmaceutical composition for the treatment of prolapse of lumbar intervertebral disc is preferably used in, is made up of the crude drug of following weight portion：
The weight portion of 206 weight portion Radix seu caulis chonemorphae valvatae of Herba sopubiae Trifidae 565 weight portion Radix Euonymi myrianthi, 503 weight portion Hydroxyevodiamine 55 is accumulated The snow weight portion of oxalic acid 13.
A kind of pharmaceutical composition for treating prolapse of lumbar intervertebral disc, it is characterised in that pharmaceutical composition can adopt galenic pharmacy Conventional method prepares piece agent or capsule or drop pill.
A kind of pharmaceutical composition for treating prolapse of lumbar intervertebral disc, it is characterised in that pharmaceutical composition and chemical drugs or Chinese medicine group Into treatment prolapse of lumbar intervertebral disc medicine.
A kind of preparation method of the pharmaceutical composition for treating prolapse of lumbar intervertebral disc, it is characterised in that prepare as follows：
The composition and weight portion of crude drug be：Herba sopubiae Trifidae 562-568 weight portion Radix Euonymi myrianthi 500-506 weight portion hydroxyl Wus Fructus Evodiae alkali 204-208 weight portion Radix seu caulis chonemorphae valvatae 50-60 weight portion asiatic acid 12-14 weight portions；
Preparation method：
（1）Herba sopubiae Trifidae, Radix Euonymi myrianthi, Hydroxyevodiamine, Radix seu caulis chonemorphae valvatae, asiatic acid are taken by crude drug proportioning, is mixed, use weight The ethanol of percent concentration 34.5% is extracted as solvent in 33.5 DEG C of warm macerating, and extraction time is 23 times, each extraction time 28.5 Hour, each solvent load is 35 times of crude drug gross weight, filters, and obtains medicinal residues A and extracting solution A, and extracting solution A reclaims ethanol, Relative density 1.08 is concentrated into, is filtered, medicinal liquid is first washed with water by LSD280 macroporous adsorptive resins, then uses weight percent The ethanol solution eluting LSD280 macroporous adsorptive resins of specific concentration 22.5%, collect the ethanol elution of weight percent concentration 22.5% Liquid, reclaims ethanol, and concentrate drying obtains final product extract A；
（2）Take step（1）Medicinal residues A, with the ethanol of weight percent concentration 52.5% as solvent, heating and refluxing extraction 13 times, every time Extraction time is 0.6 hour, and each solvent load is 44 times of medicinal residues A weight, filters, and obtains medicinal residues B and extracting solution B, extracting solution B Ethanol is reclaimed, relative density 1.06 is concentrated into, is filtered, medicinal liquid is first washed with water by HP-2MG macroporous adsorptive resins, then is used The ethanol solution eluting HP-2MG macroporous adsorptive resins of weight percent concentration 64.5%, collect the second of weight percent concentration 64.5% Alcohol eluen, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Preferred a kind of preparation method of the pharmaceutical composition for treating prolapse of lumbar intervertebral disc, it is characterised in that as follows Prepare：
The composition and weight portion of crude drug be：The weight portion Hydroxyevodiamine of 565 weight portion Radix Euonymi myrianthi of Herba sopubiae Trifidae 503 The weight portion of 206 weight portion Radix seu caulis chonemorphae valvatae, 55 weight portion asiatic acid 13；
Preparation method：
（1）Herba sopubiae Trifidae, Radix Euonymi myrianthi, Hydroxyevodiamine, Radix seu caulis chonemorphae valvatae, asiatic acid are taken by crude drug proportioning, is mixed, use weight The ethanol of percent concentration 34.5% is extracted as solvent in 33.5 DEG C of warm macerating, and extraction time is 23 times, each extraction time 28.5 Hour, each solvent load is 35 times of crude drug gross weight, filters, and obtains medicinal residues A and extracting solution A, and extracting solution A reclaims ethanol, Relative density 1.08 is concentrated into, is filtered, medicinal liquid is first washed with water by LSD280 macroporous adsorptive resins, then uses weight percent The ethanol solution eluting LSD280 macroporous adsorptive resins of specific concentration 22.5%, collect the ethanol elution of weight percent concentration 22.5% Liquid, reclaims ethanol, and concentrate drying obtains final product extract A；
（2）Take step（1）Medicinal residues A, with the ethanol of weight percent concentration 52.5% as solvent, heating and refluxing extraction 13 times, every time Extraction time is 0.6 hour, and each solvent load is 44 times of medicinal residues A weight, filters, and obtains medicinal residues B and extracting solution B, extracting solution B Ethanol is reclaimed, relative density 1.06 is concentrated into, is filtered, medicinal liquid is first washed with water by HP-2MG macroporous adsorptive resins, then is used The ethanol solution eluting HP-2MG macroporous adsorptive resins of weight percent concentration 64.5%, collect the second of weight percent concentration 64.5% Alcohol eluen, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
A kind of preparation method of the pharmaceutical composition for treating prolapse of lumbar intervertebral disc, it is characterised in that pharmaceutical composition can be adopted Piece agent or capsule or drop pill are prepared with the conventional method of galenic pharmacy.
A kind of preparation method of the pharmaceutical composition for treating prolapse of lumbar intervertebral disc, it is characterised in that pharmaceutical composition and chemistry Medicine or Chinese medicine composition treatment prolapse of lumbar intervertebral disc medicine.
Medicine composite for curing prolapse of lumbar intervertebral disc is evident in efficacy.
Specific embodiment
Embodiment 1：Pharmaceutical composition for the treatment of prolapse of lumbar intervertebral disc and preparation method thereof
Treatment prolapse of lumbar intervertebral disc pharmaceutical composition crude drug composition and weight portion be：Herba sopubiae Trifidae 565g is big, and fruit is defended Lance 503g Hydroxyevodiamine 206g Radix seu caulis chonemorphae valvatae 55g asiatic acid 13g；
Preparation method：
（1）Herba sopubiae Trifidae, Radix Euonymi myrianthi, Hydroxyevodiamine, Radix seu caulis chonemorphae valvatae, asiatic acid are taken by crude drug proportioning, is mixed, use weight The ethanol of percent concentration 34.5% is extracted as solvent in 33.5 DEG C of warm macerating, and extraction time is 23 times, each extraction time 28.5 Hour, each solvent load is 35 times of crude drug gross weight, filters, and obtains medicinal residues A and extracting solution A, and extracting solution A reclaims ethanol, Relative density 1.08 is concentrated into, is filtered, medicinal liquid is first washed with water by LSD280 macroporous adsorptive resins, then uses weight percent The ethanol solution eluting LSD280 macroporous adsorptive resins of specific concentration 22.5%, collect the ethanol elution of weight percent concentration 22.5% Liquid, reclaims ethanol, and concentrate drying obtains final product extract A；
（2）Take step（1）Medicinal residues A, with the ethanol of weight percent concentration 52.5% as solvent, heating and refluxing extraction 13 times, every time Extraction time is 0.6 hour, and each solvent load is 44 times of medicinal residues A weight, filters, and obtains medicinal residues B and extracting solution B, extracting solution B Ethanol is reclaimed, relative density 1.06 is concentrated into, is filtered, medicinal liquid is first washed with water by HP-2MG macroporous adsorptive resins, then is used The ethanol solution eluting HP-2MG macroporous adsorptive resins of weight percent concentration 64.5%, collect the second of weight percent concentration 64.5% Alcohol eluen, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Embodiment 2：Pharmaceutical composition for the treatment of prolapse of lumbar intervertebral disc and preparation method thereof
Treatment prolapse of lumbar intervertebral disc pharmaceutical composition crude drug composition and weight portion be：Herba sopubiae Trifidae 562g is big, and fruit is defended Lance 506g Hydroxyevodiamine 204g Radix seu caulis chonemorphae valvatae 60g asiatic acid 12g；
Preparation method：
（1）Herba sopubiae Trifidae, Radix Euonymi myrianthi, Hydroxyevodiamine, Radix seu caulis chonemorphae valvatae, asiatic acid are taken by crude drug proportioning, is mixed, use weight The ethanol of percent concentration 34.5% is extracted as solvent in 33.5 DEG C of warm macerating, and extraction time is 23 times, each extraction time 28.5 Hour, each solvent load is 35 times of crude drug gross weight, filters, and obtains medicinal residues A and extracting solution A, and extracting solution A reclaims ethanol, Relative density 1.08 is concentrated into, is filtered, medicinal liquid is first washed with water by LSD280 macroporous adsorptive resins, then uses weight percent The ethanol solution eluting LSD280 macroporous adsorptive resins of specific concentration 22.5%, collect the ethanol elution of weight percent concentration 22.5% Liquid, reclaims ethanol, and concentrate drying obtains final product extract A；
（2）Take step（1）Medicinal residues A, with the ethanol of weight percent concentration 52.5% as solvent, heating and refluxing extraction 13 times, every time Extraction time is 0.6 hour, and each solvent load is 44 times of medicinal residues A weight, filters, and obtains medicinal residues B and extracting solution B, extracting solution B Ethanol is reclaimed, relative density 1.06 is concentrated into, is filtered, medicinal liquid is first washed with water by HP-2MG macroporous adsorptive resins, then is used The ethanol solution eluting HP-2MG macroporous adsorptive resins of weight percent concentration 64.5%, collect the second of weight percent concentration 64.5% Alcohol eluen, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Embodiment 3：Pharmaceutical composition for the treatment of prolapse of lumbar intervertebral disc and preparation method thereof
Treatment prolapse of lumbar intervertebral disc pharmaceutical composition crude drug composition and weight portion be：Herba sopubiae Trifidae 568g is big, and fruit is defended Lance 500g Hydroxyevodiamine 208g Radix seu caulis chonemorphae valvatae 50g asiatic acid 14g；
Preparation method：
（1）Herba sopubiae Trifidae, Radix Euonymi myrianthi, Hydroxyevodiamine, Radix seu caulis chonemorphae valvatae, asiatic acid are taken by crude drug proportioning, is mixed, use weight The ethanol of percent concentration 34.5% is extracted as solvent in 33.5 DEG C of warm macerating, and extraction time is 23 times, each extraction time 28.5 Hour, each solvent load is 35 times of crude drug gross weight, filters, and obtains medicinal residues A and extracting solution A, and extracting solution A reclaims ethanol, Relative density 1.08 is concentrated into, is filtered, medicinal liquid is first washed with water by LSD280 macroporous adsorptive resins, then uses weight percent The ethanol solution eluting LSD280 macroporous adsorptive resins of specific concentration 22.5%, collect the ethanol elution of weight percent concentration 22.5% Liquid, reclaims ethanol, and concentrate drying obtains final product extract A；
（2）Take step（1）Medicinal residues A, with the ethanol of weight percent concentration 52.5% as solvent, heating and refluxing extraction 13 times, every time Extraction time is 0.6 hour, and each solvent load is 44 times of medicinal residues A weight, filters, and obtains medicinal residues B and extracting solution B, extracting solution B Ethanol is reclaimed, relative density 1.06 is concentrated into, is filtered, medicinal liquid is first washed with water by HP-2MG macroporous adsorptive resins, then is used The ethanol solution eluting HP-2MG macroporous adsorptive resins of weight percent concentration 64.5%, collect the second of weight percent concentration 64.5% Alcohol eluen, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Embodiment 4：The preparation of tablet
The pharmaceutical composition 364g of Example 1, adds starch 265g, mixes, and granulation is dried, plus Microcrystalline Cellulose 154g, Hard Fat Sour magnesium 11.5g, mixes, and is pressed into 1600, obtains final product medicinal composition tablets.
Embodiment 5：The preparation of capsule
The pharmaceutical composition 405.5g of Example 2, adds starch 357.5g, mixes, and granulation is dried, granulate, adds appropriate Hard Fat Sour magnesium, mixes, and encapsulated 1600, obtains final product medicament composition capsule.
Embodiment 6：The preparation of drop pill
Weigh (80 DEG C) heating of polyethylene glycol 6000 240.5g water-baths and boil molten, add the pharmaceutical composition 12.5g of embodiment 3, fill Divide and stir, with liquid paraffin as coolant, put glass tubing（4*80cm）In, chilling temperature is -3 DEG C, and drip internal-and external diameter is 7.0/2.0 (mm/mm), drip is 2.3cm away from liquid level, and drop speed, as optimum condition, with cotton drop pill surface is blotted with per point 52 drops Condensing agent, obtain final product medicament composition dropping pills.
Experimental example 1：The experimental study for the treatment of prolapse of lumbar intervertebral disc
1 data and method
1. 1 physical data
According to entering group treatment time sequencing by this city hospital 60 prolapse of lumbar intervertebral disc of December -2014 years in Mays, 2013 Disease patient is divided into matched group and seminar, 30 per group.Meet People's Republic of China's traditional Chinese medicine industry standard Chinese medical disease Standardization of diagnosis and curative effect.There is chronic strain or waist wound or damp disease history of catching cold in patient；Some patientss exist chronic in premorbid Lumbago medical history, in being apt to occur in Young crowd；Scoliosis and the disappearance of waist physiology radians；There is tenderness by diseased region vertebra, And to lower limb radiation etc..Jing CT or nuclear magnetic resonance (MRI) are checked is made a definite diagnosis.Seminar man 15, female 15；Age 26-66 year, year mean age (52.4 ± 3.3)；Course of disease 0.3-2.1, average course of disease (1.5 ± 0.4) year.Matched group man 15 Example, female 15；Age 27-64 year, year mean age (50.6 ± 1.8)；Course of disease 0.5-2.1, average course of disease (1.6 ± 0.1) year.Two groups of patient's physical data compare, no significant difference (P>0.05), with comparability.
1. 2 method
Matched group gives acupuncture and moxibustion therapy；Choose in the Large Intestine Shu and shen shu and Huantiao and bl 26, tsu san li, chengshan, committee, Yang Ling Spring, Xuanzhong acupuncture point.Dorsal positions at patient, sterilize around selected acupuncture point, and select the acupuncture acupuncture of suitable length, so Uniform reinforcing-reducing method is adopted afterwards, acupuncture point is sticked a needle into until bringing about the desired sensation, and then carries slotting twisted again, let the acupuncture needle remain at a certain point 20min, per 10 minutes The hand-manipulating of needle 1 time.Seminar is treated using pharmaceutical composition (pharmaceutical composition of embodiment 1), 0.7g/ time, 3 times/d.Two groups Patient treats 20 d.
1. 3 observation index
Two groups are treated observation and treatment effect and untoward reaction after 20 d.
1. 4 the standard of curative effect evaluation
Its clinical efficacy is evaluated according to patient clinical symptom and sign.Cure：Jing after treatment, patient's lumbago and skelalgia is wholly absent, Straight-leg raising test>70 °, and resume work；Effectively：After treatment, patient's lumbago and skelalgia substantially mitigates, and waist movable function is bright It is aobvious to improve；It is invalid：Patient treats pain and waist movable function without improvement, or even increases.Total effective rate=(cure+effectively)/ Total number of cases × 100%.
1. 5 statistical method
Statistical analysiss are carried out to data using SPSS18.0 statistics softwares.Measurement data is with mean ± standard deviation (x ± s) table Show, checked using t；Enumeration data is represented with rate (%), using X 2 test.P<There are 0.05 expression difference statistics to anticipate Justice.
2 results
Jing after treating 20 d, seminar cures 17, effective 11, invalid 2；Matched group healing 10, effective 12 Example, invalid 8.Seminar's cure rate is 56.67% apparently higher than the 33.33% of matched group, the statistically significant (P of difference< 0.05).Seminar's total effective rate is 93.33% to compare with the 73.33% of matched group, the statistically significant (P of difference<0.05). During treatment, there is no untoward reaction in two groups of patients.

Claims (8)

1. a kind of pharmaceutical composition for treating prolapse of lumbar intervertebral disc, it is characterised in that make the group of the crude drug of the pharmaceutical composition It is into weight portion：
Herba sopubiae Trifidae 562-568 weight portion Radix Euonymi myrianthi 500-506 weight portion Hydroxyevodiamine 204-208 weight portion rattans Secondary 50-60 weight portions asiatic acid 12-14 weight portions.
2. a kind of pharmaceutical composition for treating prolapse of lumbar intervertebral disc according to claim 1, it is characterised in that make the medicine The composition and weight portion of the crude drug of compositionss be：
The weight portion of 206 weight portion Radix seu caulis chonemorphae valvatae of Herba sopubiae Trifidae 565 weight portion Radix Euonymi myrianthi, 503 weight portion Hydroxyevodiamine 55 is accumulated The snow weight portion of oxalic acid 13.
3. a kind of pharmaceutical composition for treating prolapse of lumbar intervertebral disc according to claim 1, it is characterised in that pharmaceutical composition The conventional method that galenic pharmacy can be adopted prepares piece agent or capsule or drop pill.
4. a kind of pharmaceutical composition for treating prolapse of lumbar intervertebral disc according to claim 1, it is characterised in that pharmaceutical composition The treatment prolapse of lumbar intervertebral disc medicine constituted with chemical drugs or Chinese medicine.
5. a kind of preparation method of the pharmaceutical composition for treating prolapse of lumbar intervertebral disc, it is characterised in that prepare as follows：
The composition and weight portion of crude drug be：Herba sopubiae Trifidae 562-568 weight portion Radix Euonymi myrianthi 500-506 weight portion hydroxyl Wus Fructus Evodiae alkali 204-208 weight portion Radix seu caulis chonemorphae valvatae 50-60 weight portion asiatic acid 12-14 weight portions；
Preparation method：
（1）Herba sopubiae Trifidae, Radix Euonymi myrianthi, Hydroxyevodiamine, Radix seu caulis chonemorphae valvatae, asiatic acid are taken by crude drug proportioning, is mixed, use weight The ethanol of percent concentration 34.5% is extracted as solvent in 33.5 DEG C of warm macerating, and extraction time is 23 times, each extraction time 28.5 Hour, each solvent load is 35 times of crude drug gross weight, filters, and obtains medicinal residues A and extracting solution A, and extracting solution A reclaims ethanol, Relative density 1.08 is concentrated into, is filtered, medicinal liquid is first washed with water by LSD280 macroporous adsorptive resins, then uses weight percent The ethanol solution eluting LSD280 macroporous adsorptive resins of specific concentration 22.5%, collect the ethanol elution of weight percent concentration 22.5% Liquid, reclaims ethanol, and concentrate drying obtains final product extract A；
（2）Take step（1）Medicinal residues A, with the ethanol of weight percent concentration 52.5% as solvent, heating and refluxing extraction 13 times, every time Extraction time is 0.6 hour, and each solvent load is 44 times of medicinal residues A weight, filters, and obtains medicinal residues B and extracting solution B, extracting solution B Ethanol is reclaimed, relative density 1.06 is concentrated into, is filtered, medicinal liquid is first washed with water by HP-2MG macroporous adsorptive resins, then is used The ethanol solution eluting HP-2MG macroporous adsorptive resins of weight percent concentration 64.5%, collect the second of weight percent concentration 64.5% Alcohol eluen, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
6. a kind of preparation method of the pharmaceutical composition for treating prolapse of lumbar intervertebral disc according to claim 5, it is characterised in that Prepare as follows：
The composition and weight portion of crude drug be：The weight portion Hydroxyevodiamine of 565 weight portion Radix Euonymi myrianthi of Herba sopubiae Trifidae 503 The weight portion of 206 weight portion Radix seu caulis chonemorphae valvatae, 55 weight portion asiatic acid 13；
Preparation method：
（1）Herba sopubiae Trifidae, Radix Euonymi myrianthi, Hydroxyevodiamine, Radix seu caulis chonemorphae valvatae, asiatic acid are taken by crude drug proportioning, is mixed, use weight The ethanol of percent concentration 34.5% is extracted as solvent in 33.5 DEG C of warm macerating, and extraction time is 23 times, each extraction time 28.5 Hour, each solvent load is 35 times of crude drug gross weight, filters, and obtains medicinal residues A and extracting solution A, and extracting solution A reclaims ethanol, Relative density 1.08 is concentrated into, is filtered, medicinal liquid is first washed with water by LSD280 macroporous adsorptive resins, then uses weight percent The ethanol solution eluting LSD280 macroporous adsorptive resins of specific concentration 22.5%, collect the ethanol elution of weight percent concentration 22.5% Liquid, reclaims ethanol, and concentrate drying obtains final product extract A；
（2）Take step（1）Medicinal residues A, with the ethanol of weight percent concentration 52.5% as solvent, heating and refluxing extraction 13 times, every time Extraction time is 0.6 hour, and each solvent load is 44 times of medicinal residues A weight, filters, and obtains medicinal residues B and extracting solution B, extracting solution B Ethanol is reclaimed, relative density 1.06 is concentrated into, is filtered, medicinal liquid is first washed with water by HP-2MG macroporous adsorptive resins, then is used The ethanol solution eluting HP-2MG macroporous adsorptive resins of weight percent concentration 64.5%, collect the second of weight percent concentration 64.5% Alcohol eluen, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
7. a kind of preparation method of the pharmaceutical composition for treating prolapse of lumbar intervertebral disc according to claim 5, it is characterised in that Pharmaceutical composition can adopt the conventional method of galenic pharmacy to prepare piece agent or capsule or drop pill.
8. a kind of preparation method of the pharmaceutical composition for treating prolapse of lumbar intervertebral disc according to claim 5, it is characterised in that Pharmaceutical composition and chemical drugs or Chinese medicine composition treatment prolapse of lumbar intervertebral disc medicine.
CN201611132987.8A 2016-12-10 2016-12-10 Pharmaceutical composition for treating lumbar disc herniation and preparation method thereof Withdrawn CN106581263A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201611132987.8A CN106581263A (en) 2016-12-10 2016-12-10 Pharmaceutical composition for treating lumbar disc herniation and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201611132987.8A CN106581263A (en) 2016-12-10 2016-12-10 Pharmaceutical composition for treating lumbar disc herniation and preparation method thereof

Publications (1)

Publication Number Publication Date
CN106581263A true CN106581263A (en) 2017-04-26

Family

ID=58598449

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201611132987.8A Withdrawn CN106581263A (en) 2016-12-10 2016-12-10 Pharmaceutical composition for treating lumbar disc herniation and preparation method thereof

Country Status (1)

Country Link
CN (1) CN106581263A (en)

Similar Documents

Publication Publication Date Title
CN102861287B (en) Chinese medicinal composition for treating damp-heat invasion blood stasis diabetic foot and preparation method thereof
CN102772712B (en) Traditional Chinese medicine composition for treating heat-toxicity, flourishing and blood stasis type diabetic foot
CN106668348A (en) Pharmaceutical composition for treating diabetic retinopathy
CN106109564A (en) Pharmaceutical composition for the treatment of cerebral thrombosis and preparation method thereof
CN104857366A (en) Preoperative intervention medicine composition for neurosurgery and application thereof
CN103845450A (en) Application of hawthorns in preparing medicine for treating hyperuricemia, gout and renal insufficiency
CN106581263A (en) Pharmaceutical composition for treating lumbar disc herniation and preparation method thereof
CN104324139B (en) A kind of pharmaceutical composition treating xerophthalmia
CN106109927A (en) A kind of pharmaceutical composition treating chloasma and preparation method thereof
CN106727854A (en) A kind of pharmaceutical composition for treating synovitis
CN106729101B (en) Traditional Chinese medicine composition for treating post-circulation ischemic stroke and preparation method thereof
CN106540011A (en) The pharmaceutical composition of preventing and treating senile osteoporosis
CN105497095A (en) Medicine composition for treating esophagus cancer at middle and late stages
CN106728299A (en) It is a kind of to treat pharmaceutical composition of protrusion of lumber intervertebral disc and preparation method thereof
CN105267684A (en) Traditional Chinese medicine for treating chemotherapeutic phlebitis of tumor patients and preparation method thereof
CN104225506A (en) Medicinal preparation for treating thrombocytopenia after chemotherapy
CN103550284A (en) Traditional Chinese medicine composition for treating urinary calculus and preparation method thereof
CN104587376A (en) Drug for treating qi stagnation and blood stasis-type thoracic obstruction and preparation method of drug oral liquid
CN106727874A (en) It is a kind of to prevent and treat pharmaceutical composition of ovarian cyst and preparation method thereof
CN106727851A (en) Prevent and treat pharmaceutical composition of ovarian cyst and preparation method thereof
CN106668183A (en) Pharmaceutical composition for treating epilepsy and preparation method thereof
CN106581102A (en) Pharmaceutical composition for treatment of uterine myoma
CN106539958A (en) The pharmaceutical composition for the treatment of prolapse of lumbar intervertebral disc
CN106581326A (en) Pharmaceutical composition for preventing and treating senile osteoporosis
CN106540089A (en) Pharmaceutical composition for the treatment of rheumatoid arthritiss and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20170426

WW01 Invention patent application withdrawn after publication